Technical analysis of Monte Rosa Therapeutics, Inc. (GLUE): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers.
Price Performance
| 1 month | -15.83% |
| 3 months | -30.91% |
| Year-to-date | -19.32% |
| 1 year | +98.90% |
| 3 years | +110.13% |
| 5 years | -58.84% |
52-Week Range
| 52-week High | $25.77 |
| 52-week Low | $6.16 |
| Avg Volume (90d) | 1.3M |
Technical Indicators
| SMA 50 | $17.61 |
| SMA 200 | $18.48 |
| Beta | 1.64 |
| 30-day Volatility (annualised) | 48.4% |
| Price vs SMA 50 | -28.2% |
| Price vs SMA 200 | -31.6% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $12.85 | |
| 2025-11 | $16.17 | +25.8% |
| 2025-12 | $15.68 | -3.0% |
| 2026-01 | $20.52 | +30.9% |
| 2026-02 | $17.75 | -13.5% |
| 2026-03 | $16.45 | -7.3% |
| 2026-04 | $19.15 | +16.4% |
| 2026-05 | $19.71 | +2.9% |
| 2026-06 | $24.20 | +22.8% |
| 2026-07 | $16.52 | -31.7% |
| 2026-08 | $13.94 | -15.6% |
| 2026-09 | $12.65 | -9.3% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-15 | | |
| 2026-09-15 | | $7M |
| 2026-09-15 | | |
| 2026-09-15 | | |
| 2026-09-15 | $0.18 | $3.02B |
| 2026-09-15 | | |
Price
| Price | $12.60 |
| Market Cap | $1.1B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 2.38 |
| EV / EBITDA | -7.17 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.08 |
| Current Ratio | 9.52 |